<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04139525</url>
  </required_header>
  <id_info>
    <org_study_id>0120-11/2019/3</org_study_id>
    <nct_id>NCT04139525</nct_id>
  </id_info>
  <brief_title>Comparison of Citrate and Heparin Anticoagulation During Hemodialysis With MCO PES-PVP (Theranova) Membrane</brief_title>
  <official_title>Comparison of Citrate and Heparin Anticoagulation During Hemodialysis With Medium Cut-off Polyarylethersulphone- Polyvinylpirrolidone (Theranova) Membrane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marija Malgaj Vrečko</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the efficiency and biocompatibility of citrate and&#xD;
      heparin anticoagulation during hemodialysis with medium cut-off&#xD;
      polyarylethersulphone-polyvinylpirrolidone membrane (Theranova®).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to compare the efficiency and biocompatibility of citrate and&#xD;
      heparin anticoagulation during hemodialysis (HD) with PES-PVP membrane. The research will be&#xD;
      performed as a prospective clinical trial and will include 35 patients. Every patient will&#xD;
      have 2 HD procedures with PES-PVP membrane in a randomized order: 1 with unfractionated&#xD;
      heparin (UFH) and 1 with 8% trisodium citrate. We will compare the efficiency of both types&#xD;
      of anticoagulation by measuring overall and instantaneous clearances of small, middle and&#xD;
      protein-bound molecules (urea, creatinine, phosphate, β2-microglobulin, p-cresol).&#xD;
      Biocompatibility will be evaluated by measuring activation of: complement (serum&#xD;
      concentration of C3a and C5a), leukocytes (serum concentration of myeloperoxidase) and&#xD;
      thrombocytes (serum concentration of PF4). We will also monitor complete blood count for&#xD;
      occurrence of leukopenia and thrombocytopenia. After the HD electron microscopy of the&#xD;
      membrane will be done in the proportion of included patients to evaluate adsorption of cells&#xD;
      and formation of blood clots on the membrane.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The research will be performed as a prospective clinical trial. Every patient will have 2 HD procedures with PES-PVP membrane in a randomized order: 1 with unfractionated heparin (UFH) and 1 with 8% trisodium citrate.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance of beta-2 microglobulin</measure>
    <time_frame>At the end of each hemodialysis procedure.</time_frame>
    <description>Overall and instantaneous clearance of beta-2 microglobulin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of phosphate</measure>
    <time_frame>At the end of each hemodialysis procedure.</time_frame>
    <description>Overall and instantaneous clearance of phosphate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of C3a, C5a, myeloperoxidase and PF-4</measure>
    <time_frame>At the start, after 15 minutes and at the end of each hemodialysis procedure.</time_frame>
    <description>Blood for the laboratory measurements will be taken from the arterial line.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance of urea</measure>
    <time_frame>At the end of each hemodialysis procedure.</time_frame>
    <description>Overall and instantaneous clearance of urea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of creatinine</measure>
    <time_frame>At the end of each hemodialysis procedure.</time_frame>
    <description>Overall and instantaneous clearance of creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of p-cresol</measure>
    <time_frame>At the end of each hemodialysis procedure.</time_frame>
    <description>Overall and instantaneous clearance of p-cresol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell count</measure>
    <time_frame>At the start, after 15 minutes and at the end of each hemodialysis procedure.</time_frame>
    <description>Blood for the laboratory measurements will be taken from the arterial line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood platelet count</measure>
    <time_frame>At the start, after 15 minutes and at the end of each hemodialysis procedure.</time_frame>
    <description>Blood for the laboratory measurements will be taken from the arterial line.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Haemodialysis</condition>
  <condition>Anticoagulation</condition>
  <arm_group>
    <arm_group_label>unfractionated heparin and 8% trisodium citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unfractionated heparin and 8% trisodium citrate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>unfractionated heparin</intervention_name>
    <description>A bolus of 30 I.U./kg at the start of hemodialysis, followed by 18 I.U./kg per every hour of hemodialysis.</description>
    <arm_group_label>unfractionated heparin and 8% trisodium citrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>8% trisodium citrate</intervention_name>
    <description>8% trisodium citrate in the dose of 150 ml/h.</description>
    <arm_group_label>unfractionated heparin and 8% trisodium citrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient on chronic hemodialysis&#xD;
&#xD;
          -  age 18 years old or more&#xD;
&#xD;
          -  being able to give an informed consent to participate in the survey&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  on therapeutic anticoagulation&#xD;
&#xD;
          -  citrate or heparin contraindicated&#xD;
&#xD;
          -  citrate or heparin intolerance&#xD;
&#xD;
          -  acute renal failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marija Malgaj Vrečko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Ljubljana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marija Malgaj Vrečko, MD</last_name>
    <phone>0038641813764</phone>
    <email>marija.malgaj@kclj.si</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marija Malgaj Vrečko</last_name>
      <phone>0038641813764</phone>
      <email>marija.malgaj@kclj.ci</email>
    </contact>
    <investigator>
      <last_name>Marija Malgaj Vrečko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 12, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Marija Malgaj Vrečko</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

